Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
Abstract Background Alopecia areata (AA) is an autoimmune hair loss disorder associated with high rates of emotional and psychosocial distress. Baricitinib, an oral selective Janus kinase (JAK) 1 and JAK 2 inhibitor, was superior to placebo with respect to hair regrowth in two phase 3 trials involvi...
Сохранить в:
| Главные авторы: | , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Wiley
2024-03-01
|
| Серии: | JEADV Clinical Practice |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1002/jvc2.269 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|